Annual Report

Overview

The report describes Pharming's 2022 financial growth, with revenues of US$205.6 million and operating profit of US$18.2 million. Year-end employment increased to 390 people from 321 in 2021. Pharming also established an ESG steering committee and launched an ESG program during the year. The report further records the subsequent U.S. FDA approval of Joenja on March 24, 2023, following regulatory progress during 2022.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: Ends 31 December 2022
Publication date: 4 April 2023
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services